HUB Organoids

Organoid technology enables testing of antibody-drug conjugate efficacy, safety, and tumor antigen expression, as well as discovery of response biomarkers.

HUB Organoids offers patient-derived models to accelerate KRAS-targeted drug discovery, including predictive screens, resistance models, and a diverse biobank.

Selective KRAS inhibitors show limited effectiveness in colorectal cancer, prompting combination strategies targeting EGFR and PI3Kα, though resistance remains a challenge.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 25% of the global population, with early-stage disease remaining largely untreated. It progresses from simple steatosis to severe conditions like fibrosis and hepatocellular carcinoma.

Late-stage clinical failure drives most waste in drug research and development, with trials consuming the majority of sunk capital and leaving companies vulnerable to multi-hundred-million-dollar losses when late-stage candidates fail.

HUB Organoids B.V. uses organoid technology to improve preclinical and clinical drug development accuracy and efficiency. Frost & Sullivan recognized HUB with the 2024 Global Technology Innovation Leadership Award for its advancements in this field.

HUB Organoids launched IntegriGut Screen, a screening service using IBD patient-derived organoid monolayers to provide high-quality human data on epithelial barrier function.

News - HUB Organoids

The company applies HUB Organoid Technology globally to benefit patients and encourages employees to innovate and develop their capabilities.

Dear Valued Customer, On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. These are very difficult and challenging times for every organization.

The company developed organoids from mouse intestine in 2009 and human intestinal epithelium in 2011. It established the Hubrecht Organoid Technology Foundation in 2013 to commercialize the technology and treated the first cystic fibrosis patient using organoid data in 2015.

The company provides contact options, including a phone number, chatbot, and email for general inquiries.

HUB Organoids develops patient-derived ‘mini-organs’ from healthy and diseased tissues to predict treatment responses and bridge lab and clinical applications.